The CDE Approved IND Application to Investigate Combination of Asieris’ APL-1202 and BeiGene’s Tislelizumab as Neoadjuvant Therapy for MIBC Patients

The Cde Approved Ind Application To Investigate Combination Of Asieris' Apl 1202 And Beigene's Tislelizumab As Neoadjuvant Therapy For Mibc Patients

Facebook Comments

Leave a Reply

CommentLuv badge